24/7 Market News Snapshot 28 July, 2025 – Entera Bio Ltd. Ordinary Shares (NASDAQ:ENTX)

July 28, 2025

DENVER, Colo., 28 July, 2025 (www.247marketnews.com) – (NASDAQ:ENTX) are discussed in this article.
Entera Bio Ltd. (NASDAQ:ENTX) is currently witnessing a notable upswing in its stock price, trading at $2.09, an increase of about 12.37% from the previous close of $1.86 in pre-market sessions. With a trading volume of 1.06 million shares, this surge reflects heightened investor interest and potential momentum. Technical indicators suggest that if this bullish trend continues, the stock might soon test resistance levels around $2.20. However, a decline below $1.90 could signal a bearish reversal, making it essential for traders to closely monitor these critical thresholds for possible entry or exit points in the fluctuating market.

In parallel, Entera has made significant regulatory strides with its product candidate, EB613, aimed at addressing osteoporosis. The U.S. Food and Drug Administration (FDA) has approved Entera’s proposal to support the New Drug Application (NDA) for EB613 based on findings from a pivotal Phase 3 clinical trial. This trial will primarily engage postmenopausal women with osteoporosis, evaluating changes in total hip Bone Mineral Density (BMD) as the primary endpoint, in addition to assessing the incidence of new or worsening vertebral fractures as a secondary measure.

This regulatory progress is particularly significant as it deviates from conventional osteoporosis studies that primarily focus on fracture rates. CEO Miranda Toledano emphasized the importance of this achievement, stating, “The FDA’s alignment with our approach demonstrates confidence in our data and fosters a faster pathway to bringing EB613 to patients in need.” EB613 aims to be the first oral, once-daily anabolic treatment for osteoporosis, addressing a critical gap in therapies since 2019. With over 200 million women affected globally, the innovative approach of EB613 presents a much-needed solution to enhance bone health and reduce fracture risks effectively. Entera’s commitment to advancing its clinical development program marks a significant step forward in transforming the treatment landscape for this prevalent condition.

Related news for (ENTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.